INFI insider filings

INFINITY PHARMACEUTICALS, INC. — 29 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-09-12. Screen INFI transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for INFI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — INFINITY PHARMACEUTICALS, INC.

FiledFormInsiderReported transactionsSource
2023-09-124Perkins Adelene Q — DirectorOption exercise (M): 768,133 · Sale (S): 410,196 @ $0.07 · Option exercise (M): 768,133 (derivative) @ $0EDGAR
2022-08-044Peluso Stephane — Chief Scientific OfficerOption exercise (M): 50,000 · Sale (S): 14,994 @ $0.66 · Option exercise (M): 50,000 (derivative) @ $0EDGAR
2022-06-164EVNIN ANTHONY B — DirectorGrant/award (A): 46,378 @ $0.68 · Grant/award (A): 45,000 (derivative) @ $0EDGAR
2022-06-164BEIER DAVID W — DirectorGrant/award (A): 45,000 (derivative) @ $0EDGAR
2022-06-164GAYNOR RICHARD — DirectorGrant/award (A): 45,000 (derivative) @ $0EDGAR
2022-06-164Agresta Samuel — DirectorGrant/award (A): 45,000 (derivative) @ $0EDGAR
2022-06-164SELBY NORMAN C — DirectorGrant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0EDGAR
2022-06-164SCHWARTZ BRIAN — DirectorGrant/award (A): 30,919 @ $0.68 · Grant/award (A): 45,000 (derivative) @ $0EDGAR
2022-03-314KANGO SUJAY — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2022-01-124Perkins Adelene Q — Chief Executive Officer, DirectorGrant/award (A): 576,100 (derivative) @ $0EDGAR
2022-01-124BLOCH LAWRENCE E — PresidentGrant/award (A): 335,000 (derivative) @ $0EDGAR
2022-01-124Tasker Seth A — Chief Business OfficerGrant/award (A): 225,000 (derivative) @ $0EDGAR
2022-01-124Peluso Stephane — Chief Scientific OfficerGrant/award (A): 87,027 (derivative) @ $0EDGAR
2022-01-124Ilaria Robert Jr. — Chief Medical OfficerGrant/award (A): 87,472 (derivative) @ $0EDGAR
2021-09-104SCHWARTZ BRIAN — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2021-09-034Ilaria Robert Jr. — Chief Medical OfficerGrant/award (A): 300,000 (derivative) @ $0EDGAR
2021-08-034Peluso Stephane — Chief Scientific OfficerGrant/award (A): 250,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2021-06-114BEIER DAVID W — DirectorGrant/award (A): 3,061 @ $3.43 · Grant/award (A): 30,000 (derivative) @ $0EDGAR
2021-06-114Agresta Samuel — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2021-06-114SELBY NORMAN C — DirectorGrant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0EDGAR
2021-06-114GAYNOR RICHARD — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2021-06-114EVNIN ANTHONY B — DirectorGrant/award (A): 3,061 @ $3.43 · Grant/award (A): 30,000 (derivative) @ $0EDGAR
2021-05-184SELBY NORMAN C — DirectorOption exercise (M): 5,000 @ $0.92 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2021-02-194BVF PARTNERS L P/IL
BIOTECHNOLOGY VALUE FUND L P
BVF I GP LLC
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC
BVF INC/IL
LAMPERT MARK N
Holdings only — no transactions reportedEDGAR
2021-02-164BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P
BVF I GP LLC
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Sale (S): 1,215,491 @ $5.37 · Sale (S): 892,467 @ $5.37 · Sale (S): 152,127 @ $5.37EDGAR
2021-01-264BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P
BVF I GP LLC
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Sale (S): 2,821,663 @ $4.14 · Sale (S): 2,458,838 @ $4.14 · Sale (S): 568,019 @ $4.14EDGAR
2020-12-234Tasker Seth A — Chief Business OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2020-12-234BLOCH LAWRENCE E — PresidentGrant/award (A): 335,000 (derivative) @ $0EDGAR
2020-12-234Perkins Adelene Q — Chief Executive Officer, DirectorGrant/award (A): 485,000 (derivative) @ $0EDGAR

Recent 8-K events — INFINITY PHARMACEUTICALS, INC.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-09-298-K1.03 — Bankruptcy or Receivership
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2023-09-138-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-09-118-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-09-018-K?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
EDGAR
2023-07-258-K?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-07-248-K1.02 — Termination of a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-07-148-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2023-07-038-K8.01 — Other EventsEDGAR
2023-06-308-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-06-208-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=INFI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs